Treatment of Lower Urinary Tract Symptoms Tied to Reduced Risk for Death in Men
Significant reductions seen in death with 1-point improvement in AUA Symptom Score, and in storage and voiding subscales
Source: renalandurologynews.com
📰 Symptom Score News
Symptom Score News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Symptom Score. Real-time updates on events, politics, business and more.
Treatment of Lower Urinary Tract Symptoms Tied to Reduced Risk for Death in Men
Significant reductions seen in death with 1-point improvement in AUA Symptom Score, and in storage and voiding subscales.
Source: empr.com
Treatment of Lower Urinary Tract Symptoms Tied to Reduced Risk for Death in Men
FRIDAY, Sept. 15, 2023 (HealthDay News) -- For men with lower urinary tract symptoms, treatment is associated with a reduced risk for death, according to a study published in the
Source: omaha.com
Camzyos Label Updated With Data on Use in Obstructive HCM Patients Eligible for SRT
The prescribing information for Camzyos (mavacamten) has been updated to include data from the phase 3 VALOR-HCM study.
Anjalit Owens Perelman School Of Medicine University Of Pennsylvania York Heart Association New York Heart Association Symptom Score
Source: empr.com
FDA Approves Supplemental New Drug Application To Expand Mavacamten Label for Obstructive Hypertrophic Cardiomyopathy
VALOR HCM is the second study to show that mavacamten can significantly reduce symptoms of obstructive hypertrophic cardiomyopathy, which includes left ventricular outflow tract.
Catherine Owen Anjalit Owens Perelman School Of Medicine Bristol Myers Squibb York Heart Association University Of Pennsylvania
Source: pharmacytimes.com
Jaktinib Displays Significant Benefit Vs Hydroxyurea in Intermediate-2/High-Risk Myelofibrosis
Patients with intermediate-2 or high-risk myelofibrosis who received the novel JAK/ACVR1 inhibitor jaktinib experienced a statistically significant improvement in the proportion of patients with a spleen-volume reduction of at least 35% from baseline at week 24 vs those who were treated with hydroxyurea.
Jie Jin Department Of Hematology Zhejiang University School Of Medicine First Affiliated Hospital Zhejiang University School Symptom Score
Source: onclive.com
NEJM Evidence Publishes Results from Registrational PIONEER Trial Demonstrating Significant Clinical Benefits of AYVAKIT® (avapritinib) in Patients with Indolent Systemic Mastocytosis
/PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that NEJM Evidence, a journal from The New England Journal of Medicine Group,...
Source: prnewswire.com